What is the appropriate vinorelbine dosing for an adult patient without hepatic or renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vinorelbine Dosing in Adults Without Hepatic or Renal Impairment

For adults without hepatic or renal impairment, vinorelbine should be dosed at 25 mg/m² IV on days 1,8,15, and 22 of a 28-day cycle when combined with cisplatin 100 mg/m², or 30 mg/m² IV weekly when used as a single agent or with cisplatin 120 mg/m² 1.

Standard Dosing Regimens

The FDA-approved dosing varies based on whether vinorelbine is used as monotherapy or in combination:

Combination Therapy with Cisplatin

Two cisplatin dosing options exist:

  • Cisplatin 100 mg/m² regimen: Vinorelbine 25 mg/m² IV on days 1,8,15, and 22 of each 28-day cycle, with cisplatin 100 mg/m² given only on day 1 1

  • Cisplatin 120 mg/m² regimen: Vinorelbine 30 mg/m² IV once weekly, with cisplatin 120 mg/m² on days 1 and 29, then every 6 weeks 1

Single Agent Therapy

Vinorelbine 30 mg/m² IV once weekly when used as monotherapy for metastatic NSCLC 1.

Administration Details

Critical administration parameters:

  • Administer as IV injection or infusion over 6 to 10 minutes 1
  • Dilute to concentration between 0.5-2 mg/mL in appropriate IV solution 1
  • Inject into side port of free-flowing IV line, followed by flushing with 75-125 mL of solution 1
  • Must only be given intravenously - proper catheter positioning is critical before injection 1

Evidence Supporting Dosing

The guideline evidence demonstrates that cisplatin plus vinorelbine achieved an overall hazard ratio for death of 0.89 (95% CI, 0.82-0.96; P=0.005) in adjuvant therapy for completely resected NSCLC 2. The JBR.10 trial specifically used cisplatin 50 mg/m² on days 1 and 8 every 4 weeks plus vinorelbine 25 mg/m² on day 1 every 3 weeks for 16 weeks, showing median overall survival of 7.8 years versus 6.1 years with observation 2.

Key Safety Monitoring

Severe myelosuppression is the primary dose-limiting toxicity and requires vigilant monitoring 1:

  • Check neutrophil counts before each dose
  • Hold treatment if neutrophils <1,000 cells/mm³
  • Reduce to 50% dose if neutrophils 1,000-1,499 cells/mm³
  • Discontinue if three consecutive weekly doses held for neutropenia 1

Additional critical warnings:

  • Risk of severe infection, septic shock, hospitalization, and death from myelosuppression 1
  • Discontinue for Grade 2 or higher peripheral neuropathy 1
  • Immediate management required for suspected extravasation 1

Common Pitfalls to Avoid

Do not confuse oral and IV dosing: Oral vinorelbine uses different doses (60-80 mg/m²) with approximately 40% bioavailability 3. The question specifically asks about standard dosing, which refers to IV administration per FDA labeling.

Ensure proper vascular access: Vinorelbine is a vesicant - extravasation can cause severe tissue damage. Verify catheter placement before each administration 1.

Do not skip pre-treatment counts: Neutrophil monitoring before each dose is mandatory, not optional, given the boxed warning for severe myelosuppression 1.

Related Questions

What is the recommended dosing, dose adjustments, contraindications, and supportive care for oral vinorelbine capsules in adult patients with metastatic non‑small cell lung cancer or metastatic breast cancer?
Can Imitrex (Sumatriptan) be given in patients with impaired renal function?
What is the recommended dosing of Caplyta (lumateperone) for adults, including adjustments for hepatic impairment, renal impairment, and elderly patients?
Is 500 mg of methocarbamol every 8 hours an appropriate dose for an adult without hepatic or renal disease?
What is the recommended dosing regimen for atogepant (migraine preventive) including adjustments for hepatic impairment and contraindications?
How should hyperkalemia be evaluated and treated in a patient with chronic alcohol use?
Does every type of anemia always present with a low hemoglobin, requiring further evaluation to determine the cause?
For a pediatric patient weighing 43.8 kg, how many milliliters of the Co‑amoxiclav suspension (457 mg/5 mL) are needed to deliver a total daily dose of 90 mg/kg?
What is the recommended dosing, dose adjustments, contraindications, and supportive care for oral vinorelbine capsules in adult patients with metastatic non‑small cell lung cancer or metastatic breast cancer?
What are the recommended treatment options for a 79‑year‑old female with ineffective esophageal motility (ineffective peristalsis occurring 80% of the time with failed swallows 40%), and how should this condition be explained to the patient?
How is tumor‑induced osteomalacia diagnosed and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.